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in Malaysia. METHODS: A non-parametric method called Data Envelopment Analy-
sis (DEA) with two assumptions : Variable Return to Scale (VRS) and Constant Return 
to Scale (CRS), was used to calculate and compare the efﬁ ciency scores for selected 
hospitals’ clinical departments between the year 1998 and 2006. DEA input oriented 
analysis indicates how the inefﬁ cient units could adjust their inputs to reach the efﬁ -
ciency frontier. RESULTS: Based on CRS model the mean efﬁ ciency scores in Hospital 
A departments were 76%. One department was around 50% and six departments 
were between 50% and 90% and three departments were more than 90%. The mean 
efﬁ ciency scores in Hospital B was 92%. In this hospital, two departments were 
between 75% and 90% and two departments had efﬁ ciency score equal 100% during 
study period. In Hospital C all departments were more than 75% and one department 
had efﬁ ciency score equals 100%. The results based on VRS model showed similar 
trends. CONCLUSIONS: The mean of efﬁ ciency score according different assump-
tions of Hospital B was higher than two other hospitals. The results showed that few 
departments are efﬁ cient and rests are considered inefﬁ cient and need to ﬁ nd optimum 
mixture of inputs combination. It is suggested that Hospital A and Hospital C should 
consider to improve their management of the resource inputs in inefﬁ cient department 
in order to enhance their efﬁ ciencies. 
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PRIORITIZATION OF HEALTH POLICY AND SYSTEM RESEARCH 
TOPICS IN THAILAND: MAKING IT SYSTEMATIC, TRANSPARENT AND 
PARTICIPATORY
Pilasant S, Yothasamut J, Tosagnuan K, Werayingyong P, Tantivess S, Teerawattananon Y
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand
OBJECTIVES: A growing concern is that health policy and system researches (HPSR) 
should address the needs of potential users, and subsequently have substantial impacts 
on policy decisions and professional practices. The purpose of this study is to describe 
the experience on the annual HPSR topic prioritization conducted by Thailand’s 
Health Systems Research Institute and its alliances. METHODS: Narrative descriptive 
and quantitative approaches were employed to illustrate the processes of and results 
from the HPSR topic prioritization in 2010. RESULTS: The prioritization process was 
carried out on the basis of systematicness and transparency, with participation by key 
stakeholders including policymakers, academics, health professionals, civil society, 
and industries. There was a call for research topic proposals from stakeholders in 
November and December 2009. A total of 120 topics suggested by 66 organizations 
were then prioritized by 90 representatives of stakeholder organizations. Multiple 
criteria introduced in this step involved policy relevance; disease burden; economic 
impact; social and ethical aspects; variation in practices; possibility of changing prac-
tices; and public concerns. It was found that topics related to diseases with high 
burden, relating to service delivery especially on health promotion and disease preven-
tion, and those submitted by central government agencies were more likely to get high 
priority than others. In addition, results from self-administrative survey demonstrated 
that over 92% of stakeholders strongly supported and expressed their interest to 
participate in the next annual topic prioritization process. CONCLUSIONS: This case 
study demonstrated that it is feasible to develop clear criteria and transparent process 
for prioritization of HPSR topics. Lessons learned from this case study can be useful 
for improving mechanism for selecting HPSR topics in other settings. 
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COMPLEXITY INCREASES UNCERTAINTY: THE IMPACT OF PBAC 
GUIDELINES (VERSION 4) ON PBAC DECISION-MAKING
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OBJECTIVES: In Australia, the Pharmaceutical Beneﬁ ts Advisory Committee (PBAC) 
makes recommendations to the Minister for Health on the reimbursement of pharma-
ceuticals. The sponsor’s submission is accepted by the PBAC if the drug is determined 
to be clinically effective and also cost-effective. New PBAC Guidelines on how to 
prepare a submission (version 4) were introduced in 2008. These new Guidelines 
sought to reduce the uncertainty for the PBAC in accepting the many inferences made 
in major submissions. We assessed whether the New Guidelines have indeed reduced 
the PBAC’s uncertainty in their decision-making. METHODS: Since June 2003 all 
PBAC recommendations have been made public on the Department of Health & 
Ageing website. Public Summary Documents (PSD) are available for PBAC consider-
ations relating to the PBS listing of medicines since July 2005 meeting. We reviewed 
all the PSDs reported during the period of July 2005 to July 2009. For each PSD, we 
estimated the average number of times that the words “uncertain/uncertainties/uncer-
tainty” appear per PSD page. We compared the results for the period before and after 
the introduction of version 4 of the PBAC Guidelines. RESULTS: The average number 
of times that the words “uncertain/uncertainties/uncertainty” appeared per PSD page 
was signiﬁ cantly higher for the period after the introduction of version 4 of the PBAC 
Guidelines compared to the period before (0.51 vs. 0.66, P < 0.00001). CONCLU-
SIONS: The introduction of version 4 of the PBAC Guidelines in 2008 has led to an 
increase in the complexity and, thus, uncertainty faced by PBAC during their delibera-
tions around reimbursement of pharmaceuticals in Australia. There was a signiﬁ cant 
30% increase in the number of times that the word “uncertain/uncertainties/uncer-
tainty” was found per PSD page compared with the period prior to the introduction 
of the version 4 of the Guidelines (2003–2008). 
HEALTH CARE USE & POLICY STUDIES – Prescribing Behavior & 
Treatment Guidelines
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OBJECTIVES: In 2006, the reimbursement system for civil-servant medical beneﬁ t 
schemes beneﬁ ciaries in Thailand was changed to direct billing system. It was 
unknown how this new system affects drug expenditures and the number of drug 
supply given to beneﬁ ciaries. This study aims to assess the effects of direct billing 
system on prescribing patterns. METHODS: This study was undertaken with retro-
spective cohort approach. We used the data recorded in databases of a university 
hospital in northern part of Thailand. We undertook the data on all patients with 
civil-servant medical beneﬁ t schemes who came to out-patients department between 
October 1, 2005 and March 31, 2007. Mean cost of medication, number of days’ 
supplies and medication possession ratio (MPR) of ﬁ ve highest costs of oral medication 
were calculated in 1 year before and after the system was changed. RESULTS: Out 
of 43,897 visits made at the hospital, 15,632 (36%) were under civil-servant medical 
beneﬁ t schemes. Eighty-eight percent (13,785/15,632) received medications during 
visit. The total costs of medication increased from 2 million to 4 million baths in 1 
year. Glucosamine, atorvastatin, rosiglitazone, clopidogrel and diacerin were highest 
used in terms of drug cost. Averages of day’s supplies based on these medications 
increased from 1.29 to 1.48 months per a prescription. Proportion of patients receiving 
medications more than 3 months, was slightly increased from 1.82% to 2.43%. Three 
out of ﬁ ve medications had higher MPR after system was changed (Relative risk 
ranged on 1.19–2.32). Two of these were statistical signiﬁ cant. CONCLUSIONS: The 
direct billing system affects prescribing patterns as indicated by trend of increased 
number of day’s supplies and higher medication possession ratio. Further evidence 
remains needed. Policymakers need to consider all relevant and important conse-
quences associated with the new system prior to making policy decision-making. 
INDIVIDUAL’S HEALTH – Clinical Outcomes Studies
PIH1
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OBJECTIVES: A systematic appraisal was conducted of published systematic reviews 
that assessed the harms associated with selective serotonergic reuptake inhibitors 
(SSRIs) in the perinatal period, both for the mother and infant. METHODS: A sys-
tematic method of literature searching and selection was employed for this review. 
Searches were conducted in EMBASE, Medline and the Cochrane Database of Sys-
tematic Reviews. Studies were eligible if they evaluated pregnancy or infant-related 
safety outcomes for SSRI use in pregnant or lactating women. RESULTS: The litera-
ture search identiﬁ ed seventeen systematic reviews and three subsequently published 
prospective cohort studies. None of the systematic reviews assessing serotonergic 
antidepressants as a group found an association with congenital malformations. An 
association between paroxetine exposure and infant cardiovascular malformations has 
been reported in the literature; however, more recent evidence from a large systematic 
review shows no relationship between paroxetine exposure and congenital cardiac 
malformations. Neonatal symptoms (such as withdrawal symptoms, lower Apgar 
score, and diminished response to pain stimulus) have been reported in 20–30% of 
infants with third trimester SSRI exposure. All of the reviews reported the symptoms 
as mild and self-limiting. Several SRs found a signiﬁ cant association between SSRI use 
in pregnancy and premature delivery, low birthweight, and admission to special care 
nurseries. There is conﬂ icting evidence regarding the long-term neurodevelopmental 
risks of serotonergic antidepressants. Although the levels of SSRIs in breast milk are 
relatively low, the evidence for the safety of antidepressant exposure via breastfeeding 
is limited. CONCLUSIONS: SSRI exposure during pregnancy is associated with 
mostly minor and temporary adverse outcomes for the newborn. The risk of these 
outcomes needs to be balanced with the risk of adverse outcomes resulting from SSRI 
withdrawal for the mother. 
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IMPACT OF HPV VACCINATION ON CERVICAL CANCER IN ASIA: 
RESULTS OF A STATIC MODEL
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1GlaxoSmithKline Biologicals, Wavre, Belgium; 2GSK Bio, Wavre, Belgium; 3Institut Català 
d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
OBJECTIVES: Estimate the potential clinical effect of HPV vaccination with a bivalent 
HPV-16/18 vaccine in Asian countries including the effect of cross-protection against 
non-vaccine oncogenic HPV types. METHODS: A static population model estimates 
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the expected annual number of cervical cancer cases (CC) and deaths prevented by HPV 
vaccination of 12-year-old girls in Asian countries (WHO classes) at steady state. Input 
data are, for each country, the incident CC cases and deaths (GLOBOCAN 2002), the 
distribution of HPV types in CC (http://www.who.int/hpvcentre) and the clinical trial 
vaccine efﬁ cacy against CIN2+ related to HPV-16/18 and HPV-31,45,33,52,58,35,
39,51,56,59 combined (cross-protection). Lifetime vaccine protection is assumed. The 
effect of vaccination coverage and the use of alternative estimates for countries without 
sufﬁ cient data are explored. RESULTS: Of 47 countries, sufﬁ cient country-speciﬁ c input 
data are available for eight (China, Japan, Iran, Indonesia, Republic of Korea, Thailand 
and Philippines). The model predicts that, with 100% vaccine coverage, the HPV-16/18 
CC and death reduction ranges from 57% (Japan: −4421 cases; −2032 deaths) to 74% 
(Thailand: −4627 cases; −1942 deaths) while cross-protection related CC and death 
reduction ranges from 9% (Iran; −102 cases, −53 deaths) to 27% (Japan; −2073 cases; 
−953 deaths). The overall reduction ranged from 78% (Iran: −873 cases, −454 deaths) 
to 89% (Indonesia: −13,375 cases; −6724 deaths; Thailand −5534 cases; −2323 deaths). 
With 70% vaccine coverage the CC cases prevented ranges from 611 to 80,052 and CC 
deaths prevented from 318 to 44,921 for Iran and India respectively. Eastern, south-
eastern, southern Asia and Asia continent distributions are available and can be used as 
a proxy for countries without sufﬁ cient HPV data. CONCLUSIONS: Modeling predicts 
HPV vaccination with a bivalent HPV-16/18 vaccine could result in substantial reduc-
tions in CC cases and deaths in Asian countries. Cross-protection could play an impor-
tant role in this reduction. 
INDIVIDUAL’S HEALTH – Cost Studies
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A COSTING STUDY COMPARING MIDWIFERY GROUP PRACTICE WITH 
USUAL CARE IN AN AUSTRALIAN METROPOLITAN HOSPITAL
Turkstra E, Toohill J, Gamble J, Scuffham PA
Grifﬁ th University, Meadowbrook, Queensland, Australia
OBJECTIVES: To undertake an economic evaluation of the costs and outcomes of 
midwifery group practice care compared with usual care in an Australian metropolitan 
hospital. METHODS: In a cohort study, pregnant women at low risk of complications 
could select to receive midwifery group practice care or usual care early in their 
pregnancy and were recruited when they were 35 weeks pregnant. Midwifery group 
practice provides care by the same two to three midwives and labor in a birth center. 
Usual care consists of women generally attending a GP or midwives antenatal clinic 
for antenatal care, followed by labor in the hospital. Costing data was collected from 
week 36 of pregnancy until 6 weeks postpartum. Costing for antenatal, labor, baby, 
and postnatal care were collected using the hospital accounting system. Women kept 
a diary with the number of antenatal and postnatal visits. Costing data on GP visits 
were calculated using the diaries and government reimbursement costs. RESULTS: 
The study included 102 women, with 52 women receiving midwifery group practice 
care and 50 women receiving usual care. Midwifery group practice care was associated 
with fewer antenatal visits, lower rate of induction and pharmacological pain relief, 
shorter stay in hospital and more postnatal visits. There were no statistical differences 
in clinical outcomes of the baby. The cost of antenatal care was similar between the 
groups; labor and baby costs were lower for midwifery group practice, while postnatal 
costs were higher in the midwifery group practice. Midwifery group practice was 
associated with a lower total cost per woman compared to usual care (A$4447 vs. 
A$5772, P = 0.047). CONCLUSIONS: For women at low risk of complications 
midwifery group practice is a cost-effective option, with better clinical outcomes and 
lower total costs. 
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OBJECTIVES: Childhood immunizations are recognized as one of the most cost-
effective health interventions. Yet little is know about the actual delivery costs, or 
variation in costs by service providers and geographic regions. This study undertook 
an economic analysis of public health delivery of childhood immunizations in Nova 
Scotia. METHODS: The analysis was performed from the perspective of the govern-
ment health-care provider for a 1-year period from April 2005 to March 2006. An 
incremental approach was used to assess the cost of delivering childhood immuniza-
tions in addition to existing services. Primary cost data collected included capital and 
recurrent costs. Total provider economic costs were estimated using a combination of 
ingredients-based costing and step-down cost allocation methodologies. Sensitivity 
analysis was used to examine the inﬂ uence of data uncertainty on cost results. Mul-
tivariate econometric analysis was used to estimate cost functions. RESULTS: Data 
was collected from four District Health Authorities in Nova Scotia, representing the 
delivery of 2951 immunizations. Average cost per immunization ranged from $51 to 
$105 when delivered in main public health ofﬁ ces and $45 to $150 when delivered 
in off-site clinics. The main cost driver was personnel costs. Econometric analysis 
showed a link between average cost and volume of service delivery. CONCLUSIONS: 
The cost of public health delivery of childhood vaccines varies according to the volume 
of services delivered and the delivery setting. The approach developed can be applied 
to the introduction of new vaccines such as human papilloma virus. Public health 
delivery of vaccines can be efﬁ cient if programmed on the appropriate scale. 
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MEDICAL COST AND UTILIZATION FOR PATIENTS WITH 
POSTPARTUM HEMORRHAGE IN KOREA
Jang EJ, Ryu HG, Nam MH, Cho JH, Lee NR, Bae JM
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OBJECTIVES: To investigate medical cost and health resource utilization for patients 
with postpartum hemorrhage (PPH) in Korea in 2008. METHODS: This population-
based study utilized the claims data of the Korea Health Insurance Review Agency 
from January 2008 to December 2008. Patients with PPH were identiﬁ ed based on 
ICD-10 code (O72, O721, O722, O723) that occurred within 6 weeks after normal 
or cesarean delivery. Treatments for PPH were classiﬁ ed into four categories: uterine 
contraction drugs only, drugs and transfusion, drugs + transfusion + uterine artery 
embolization (UAE), and drugs + transfusion + hysterectomy. Medical costs for PPH 
patients included all costs incurred for delivery and treating PPH. Costs and length of 
stay were analyzed in regard to the mode of delivery, age, and type of hospital where 
the delivery took place. Data were analyzed using SAS. RESULTS: There were 18,142 
(4%) PPH patients out of 452,219 deliveries in Korea in 2008. The medical cost (mean 
± SD) in patients who underwent normal delivery (ND) without PPH was 610 ± 153 
US$ and 758 ± 859 US$ for patients with PPH. The medical cost in patients who 
underwent cesarean delivery (CD) without PPH was 973 ± 1403 US$ and 860 ± 511 
US$ for patients with PPH. Length of stays (mean ± SD) were 3.7 ± 1.8 days, 3.3 ± 
0.7 days, 7.7 ± 8.8 days and 7.1 ± 3.2 days for ND with PPH patients, ND without 
PPH patients, CD with PPH patients, and CD without PPH patients, respectively. The 
mean medical cost of patients who were treated with drugs only, drugs and transfu-
sion, drugs + transfusion + UAE, and drugs + transfusion + hysterectomy were 
US$628, US$1028, US$3850, and US$3501, respectively. CONCLUSIONS: The 
medical cost was higher in patients with PPH compared to patients without PPH. 
Although the medical cost of treating PPH with UAE is higher than that of hysterec-
tomy, preserving fertility seems well worth the additional cost. 
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BACKGROUND: Liver transplantation in children is an expensive health service 
excluded from the beneﬁ t package of the universal coverage (UC) scheme, which 
covers 47 million of Thais. Its high costs and exclusion from the UC beneﬁ t package 
prevent poor biliary atresia (BA) patients from access to such health care. OBJEC-
TIVES: This study aims to estimate ﬁ nancial impact of including liver transplantation 
in children in the UC beneﬁ t package. It also explores demand for, and supply of, and 
ﬁ nancial feasibility in implementing universal access to such expensive health care in 
Thailand. METHODS: Methods include comprehensive literature review, in-depth 
interviews of medical specialists in liver transplantation in three university hospitals 
about incurred costs during and after operations, and modeling budget requirements 
for expanding universal access to such medical care. RESULTS: Research ﬁ ndings 
indicate that the incidence of BA patients in Thailand is approximately 1 to 15,000 
of live births, approximately 60 new cases of BA patient annually. Only three univer-
sity hospitals in Thailand can provide liver transplantation to children with the annual 
maximum surgical capacity of 40 cases. Literature shows the survival rate of BA 
children receiving liver transplantation ranges from 83% to 94% in the ﬁ rst year, and 
82% to 92% in the ﬁ fth year. Costs of liver transplantation in the ﬁ rst year are 
approximately 1 million Baht (US$30,000). Other costs after the ﬁ rst year including 
immunosuppressive drugs and prophylaxis antibiotics range from US$360–600 per 
month. The government will spend approximately 40 million Baht in the ﬁ rst year of 
implementation. The ﬁ nancial burden will increase to 184 and 328 million Baht per 
year in the year 30th and 70th, respectively. CONCLUSIONS: The budget require-
ment for this medical care is trivial compared to the total UC budget, but can save 
lives of BA patients and improve equity in access to health care. 
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OBJECTIVES: Cervical cancers are the second highest incidence of female cancers in 
Malaysia, causing high impact on nation’s health cost and patient’s quality of life that 
can be avoided by better screening and HPV vaccination. METHODS: This is a cross 
sectional study done from 2006–2009 and respondents were interviewed from six 
public hospitals. Methods include experts’ panel discussions to estimate treatment 
costs and respondents’ interviews using costing and SF-36 quality of life (QOL) 
questionnaires. Three programs options were compared i.e., Pap smear screening; 
quadrivalent HPV vaccination and combined strategy (screening plus vaccination). 
RESULTS: Five hundred two cervical cancer patients participated in the study. Mean 
